In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex

被引:10
|
作者
Sakita, I
Horig, H
Sun, R
Wang, FM
Nathenson, SG
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA
[2] YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA
关键词
cytotoxic T lymphocyte; major histocompatibility complex class I; in vivo priming; in vitro reconstituted complex;
D O I
10.1016/0022-1759(96)00027-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The use of peptides as a vaccine is a potentially powerful immunization strategy. We explored the possibility of inducing an efficient cytotoxic T lymphocyte (CTL) mediated immune response in mice, using in vitro reconstituted major histocompatibility complex (MHC) class I/peptide complexes as the immunogen. Recombinant derived H-2K(b) and beta(2)-microglobulin (beta(2)m) were properly folded into an MHC class I complex using the vesicular stomatitis virus (VSV)-8mer from the natural nucleocapsid protein(N52-59) (RGYVYQGL), an immunodominant K-b epitope in C57BL/6 (B6) mice. After immunizing mice with the H-2K(b) class I/VSV peptide complex and a subsequent in vitro stimulation with the VSV peptide alone, a specific CTL response was demonstrated. The method was also applicable to other peptides, for example, the Sendai virus (SV) peptide(N324-332) (FAPGNYPAL). The CTL response was mediated by CD3(+)/CD8(+) T cells and was shown to be allele specific, as only peptide loaded target cells expressing the H-2K(b) allele could be recognized. It is of interest that extremely small amounts of injected MHC class I/peptide complex (i.e. 500 pg) could generate a measurable CTL response. The MHC class I/peptide complex had to be intact and properly folded to elicit an immune response, suggesting that the complex protected the peptide for internalization by antigen presenting cells (APCs) or for delivering to the proper site for peptide exchange on the cell surface of APCs. The described immunizing method can be routinely used to prime a CTL response by employing in vitro folded MHC class I/peptide complexes, without the use of adjuvants, It appears to be efficient, sensitive and specific, By using the recombinant protein system, unlimited amounts of MHC class I/peptide complex can be produced for immunization. Moreover, this protocol permits different in vitro combinations of allelic MHC class I molecules and peptide variants.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 50 条
  • [21] Acquisition of MHC:Peptide Complexes by Dendritic Cells Contributes to the Generation of Antiviral CD8+ T Cell Immunity In Vivo
    Smyth, Lesley A.
    Hervouet, Catherine
    Hayday, Thomas
    Becker, Pablo D.
    Ellis, Richard
    Lechler, Robert I.
    Lombardi, Giovanna
    Klavinskis, Linda S.
    JOURNAL OF IMMUNOLOGY, 2012, 189 (05): : 2274 - 2282
  • [22] Estimating the In Vivo Killing Efficacy of Cytotoxic T Lymphocytes across Different Peptide-MHC Complex Densities
    Garcia, Victor
    Richter, Kirsten
    Graw, Frederik
    Oxenius, Annette
    Regoes, Roland R.
    PLOS COMPUTATIONAL BIOLOGY, 2015, 11 (05)
  • [23] IN-VIVO CTL INDUCTION WITH POINT-SUBSTITUTED OVALBUMIN PEPTIDES - IMMUNOGENICITY CORRELATES WITH PEPTIDE-INDUCED MHC CLASS-I STABILITY
    LIPFORD, GB
    BAUER, S
    WAGNER, H
    HEEG, K
    VACCINE, 1995, 13 (03) : 313 - 320
  • [24] Generation of tumor peptide-specific CTL in vitro and in vivo using different populations of antigen-pulsed dendritic cells
    Giesecke, A
    Jonuleit, H
    Kandemir, A
    Paragnik, L
    Thurner, B
    Schuler, G
    Knop, J
    Enk, AH
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (01) : 216 - 216
  • [25] Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response
    Sykulev, Y
    Joo, M
    Vturina, I
    Tsomides, TJ
    Eisen, HN
    IMMUNITY, 1996, 4 (06) : 565 - 571
  • [26] CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo
    Agadjanyan, MG
    Kim, JJ
    Trivedi, N
    Wilson, DM
    Monzavi-Karbassi, B
    Morrison, LD
    Nottingham, LK
    Dentchev, T
    Tsai, A
    Dang, KS
    Chalian, AA
    Maldonado, MA
    Williams, WV
    Weiner, DB
    JOURNAL OF IMMUNOLOGY, 1999, 162 (06): : 3417 - 3427
  • [27] A novel approach to antigen-specific deletion of CTL with minimal cellular activation using α3 domain mutants of MHC class I/peptide complex
    Xu, XN
    Purbhoo, MA
    Chen, N
    Mongkolsapaya, J
    Cox, JH
    Meier, UC
    Tafuro, S
    Dunbar, PR
    Sewell, AK
    Hourigan, CS
    Appay, V
    Cerundolo, V
    Burrows, SR
    McMichael, AJ
    Screaton, GR
    IMMUNITY, 2001, 14 (05) : 591 - 602
  • [28] INDUCTION OF CTL IN-VIVO BY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-PEPTIDE COMPLEXES COVALENTLY ASSOCIATED ON THE CELL-SURFACE
    ANJUERE, F
    HORVATH, C
    CEROTTINI, JC
    LUESCHER, IF
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (06) : 1535 - 1540
  • [29] In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes
    von Herrath, MG
    Coon, B
    Lewicki, H
    Mazarguil, H
    Gairin, JE
    Oldstone, MBA
    JOURNAL OF IMMUNOLOGY, 1998, 161 (09): : 5087 - 5096
  • [30] Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo
    Novak, Hila
    Noy, Roy
    Oved, Kfir
    Segal, Dina
    Wels, Winfried S.
    Reiter, Yoram
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (02) : 329 - 336